Kirill S. Nezhdanov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kirill S. Nezhdanov has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Ludmila Yu. Milovanova
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
7 shared publications - Alexey V. Volkov
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
6 shared publications - Svetlana Yu. Milovanova
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
6 shared publications - Marina V. Taranova
Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications - Sergey V. Moiseev
Sechenov First Moscow State Medical University (Sechenov University); Lomonosov Moscow State University
3 shared publications - Marina V. Lebedeva
I.M. Sechenov First Moscow State Medical University
2 shared publications
Latest Publications
- Open Access
- 12 July 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (6) , 528-533
Gut microbiota: Historical essay and role in nephrology
The article covers the main stages of intestinal microbiota (MB) research from ancient to modern times and addresses the features of the interaction between intestinal MB and renal diseases, the gut-kidney axis. It is believed that for the first time, MB was mentioned in one of the treatises of Ayurveda, “Caraka-Samhitā” (700–100 BC), and the first use of probiotics was mentioned in Ancient China (1000 BC). In the 1670s, Antonie van Leeuwenhoek, using an advanced microscope, described protozoa and bacteria, including intestinal MB. Later, in parallel with the discoveries of Louis Pasteur and Robert Koch, intestinal MB was a subject for research, with studies by Theodor Escherich, Henri Tissier, and our compatriots S.N. Vinogradsky and I.I. Mechnikov playing an important role. The next stage in the study of intestinal MB dates back to 1994 with the beginning of the use of 16s rRNA sequencing, metascience, and the organization of global projects for the MB study, the Human Microbiome Project and METAgenomics of the Human Intestinal Tract, the purpose of which is to study its composition and interaction with the body. An example of such an interaction is the gut-kidney axis, which reflects the metabolic relationship of the kidneys and intestinal MB. Within the context of this axis, the potential therapeutic possibilities of pro-, prebiotics and synbiotics in kidney diseases are investigated. However, despite advances in the field, further research is needed to develop of the most optimal strategy for correcting microbiota disorders, including in chronic kidney diseases.
- 12 July 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (6) , 528-533
Open AccessGut microbiota: Historical essay and role in nephrology
The article covers the main stages of intestinal microbiota (MB) research from ancient to modern times and addresses the features of the interaction between intestinal MB and renal diseases, the gut-kidney axis. It is believed that for the first time, MB was mentioned in one of the treatises of Ayurveda, “Caraka-Samhitā” (700–100 BC), and the first use of probiotics was mentioned in Ancient China (1000 BC). In the 1670s, Antonie van Leeuwenhoek, using an advanced microscope, described protozoa and bacteria, including intestinal MB. Later, in parallel with the discoveries of Louis Pasteur and Robert Koch, intestinal MB was a subject for research, with studies by Theodor Escherich, Henri Tissier, and our compatriots S.N. Vinogradsky and I.I. Mechnikov playing an important role. The next stage in the study of intestinal MB dates back to 1994 with the beginning of the use of 16s rRNA sequencing, metascience, and the organization of global projects for the MB study, the Human Microbiome Project and METAgenomics of the Human Intestinal Tract, the purpose of which is to study its composition and interaction with the body. An example of such an interaction is the gut-kidney axis, which reflects the metabolic relationship of the kidneys and intestinal MB. Within the context of this axis, the potential therapeutic possibilities of pro-, prebiotics and synbiotics in kidney diseases are investigated. However, despite advances in the field, further research is needed to develop of the most optimal strategy for correcting microbiota disorders, including in chronic kidney diseases.
- 17 January 2025
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 28 (4) , 45-54
Predictive value of serum Klotho protein level in assessing: cardiovascular risk, achievement of the end stage of CKD, and overall survival of patients with initial CKD C3-4: a prospective clinical analysis (follow-up period of 8 years)
BACKGROUND. Cardiovascular complications (CVС) are the leading cause of death in a cohort of CKD patients, including young working age people. The search for a prognostic marker that allows predicting and preventing the risk of CVС is an important not only medical but also socioeconomic task.THE AIM OF THE STUDY: To determine the predictive value of baseline serum Klotho levels in assessing cardiovascular risk, risk of developing end-stage renal disease (ESRD), and overall survival among patients with stage 3-4 CKD, during an 8-year follow-up period.PATIENTS AND METHODS: The study included 75 patients with CKD C3-4, mean age 54+9 years. The initial serum Klotho level was divided into quartiles (1 quartile Klotho – 148-336 pg/ml; 2-3 quartile – 337-580 pg/ml; 4 quartile – 580-812 pg/ml). The overall survival of patients over a period of 8 years, the cause of death, and the achievement of ESRD, depending on the Klotho quartile, were assessed. RESULTS: During the observation period, 22 patients died, of which 12 (54.5 %) died from CVC, 7 (31.8 %) from covid infection, 3 (13.6 %) from other causes. When assessed by quartiles, patients with the 1st quartile prevailed among the deceased patients, including those from CVC: the 1st quartile was – 9 (75.0 %), the 2nd-3rd quartile -3 (25.0 %), the 4th quartile – 0 ( 0 %), (chi-square = 8.2, p=0.023). Among patients who achieved ESRD and started dialysis (n=30), patients with 1 quartile were 12 (63.2 %), 2-3 quartile -16 (43.2 %), 4 quartile – 2 (10.5 % ), (chi-square = 11.3, p = 0.01). Among the surviving patients (n=53) with CVC on the moment of end study (n=28), patients with 1 quartile were 19 (67.9 %), 2-3 quartile 9 (32.1 %), 4 quartile – 0 % (chisquare=19.9, pCONCLUSION: According to our data, the serum level of Klotho did not depend on the age of patients or the stage of CKD (in the sample of patients with 3-4 stages of CKD), however, it was clearly associated with the risk of cardiovascular events, the risk of progression of CKD to ESRD, overall survival of patients and can be considered as prognostic marker in patients with pre-dialysis stages of CKD.
- 17 January 2025
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 28 (4) , 45-54
Predictive value of serum Klotho protein level in assessing: cardiovascular risk, achievement of the end stage of CKD, and overall survival of patients with initial CKD C3-4: a prospective clinical analysis (follow-up period of 8 years)
BACKGROUND. Cardiovascular complications (CVС) are the leading cause of death in a cohort of CKD patients, including young working age people. The search for a prognostic marker that allows predicting and preventing the risk of CVС is an important not only medical but also socioeconomic task.THE AIM OF THE STUDY: To determine the predictive value of baseline serum Klotho levels in assessing cardiovascular risk, risk of developing end-stage renal disease (ESRD), and overall survival among patients with stage 3-4 CKD, during an 8-year follow-up period.PATIENTS AND METHODS: The study included 75 patients with CKD C3-4, mean age 54+9 years. The initial serum Klotho level was divided into quartiles (1 quartile Klotho – 148-336 pg/ml; 2-3 quartile – 337-580 pg/ml; 4 quartile – 580-812 pg/ml). The overall survival of patients over a period of 8 years, the cause of death, and the achievement of ESRD, depending on the Klotho quartile, were assessed. RESULTS: During the observation period, 22 patients died, of which 12 (54.5 %) died from CVC, 7 (31.8 %) from covid infection, 3 (13.6 %) from other causes. When assessed by quartiles, patients with the 1st quartile prevailed among the deceased patients, including those from CVC: the 1st quartile was – 9 (75.0 %), the 2nd-3rd quartile -3 (25.0 %), the 4th quartile – 0 ( 0 %), (chi-square = 8.2, p=0.023). Among patients who achieved ESRD and started dialysis (n=30), patients with 1 quartile were 12 (63.2 %), 2-3 quartile -16 (43.2 %), 4 quartile – 2 (10.5 % ), (chi-square = 11.3, p = 0.01). Among the surviving patients (n=53) with CVC on the moment of end study (n=28), patients with 1 quartile were 19 (67.9 %), 2-3 quartile 9 (32.1 %), 4 quartile – 0 % (chisquare=19.9, pCONCLUSION: According to our data, the serum level of Klotho did not depend on the age of patients or the stage of CKD (in the sample of patients with 3-4 stages of CKD), however, it was clearly associated with the risk of cardiovascular events, the risk of progression of CKD to ESRD, overall survival of patients and can be considered as prognostic marker in patients with pre-dialysis stages of CKD.
- 2 September 2024
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (1) , 171-179
α-Klotho is associated with cardiovascular and all-cause mortality in patients with stage 3b and 4 chronic kidney disease (CKD): a long-term prospective cohort study
Background α-Klotho deficiency may increase cardiovascular risks and worsen survival. We evaluated the association of α-Klotho with cardiovascular and all-cause mortality in pre-dialysis chronic kidney disease (CKD) patients. Methods In this prospective study, 75 non-diabetic CKD stage 3b–4 patients were followed-up for a median of 8 years. Primary and secondary outcomes were all-cause and cardiovascular mortality, respectively. Human soluble α-Klotho ELISA Assay (IBL-Takara 27,998-96Well), Human Fibroblast Growth Factor-23 ELISA Assay (intact FGF23, Merck Millipore MILLENZ FGF23-32 K), and Human Sclerostin ELISA kits (Biomedica, Vienna, BI-20492) were used to measure serum α-Klotho, FGF23 and sclerostin levels in the certified laboratory at the Sechenov University according to the manufacturers’ protocols. All patients underwent echocardiography to evaluate left ventricular mass index (LVMI), left ventricular ejection fraction by Simpson method, and cardiac (valve) calcification score by a semi-quantitative point scale. Lateral abdominal radiography by Kauppila method was used to estimate calcification of the abdominal aorta. Cox multivariate regression and receiver-operating characteristic curve (ROC)-analysis were used to evaluate risk factors for death and their cut-off values. Results Primary and secondary endpoints were reached in 15 (20%) and 9 (12%) patients, respectively. Median α-Klotho levels in deceased and surviving patients were 344 and 484 pg/ml, respectively (p = 0.002). In a multivariate Cox regression model, baseline α-Klotho levels (HR 0.99, 95% CI 0.98–1.00, p = 0.023), aortic calcification (HR 1.18, 95% CI 1.02–1.36, p = 0.029) and left ventricular mass index (LVMI) (HR 1.04, 95% CI 1.00–1.08, p = 0.033) were associated with the primary endpoint, whereas α-Klotho (HR 0.99, 95% CI 0.98–1.00, p = 0.029), aortic calcification (HR 1.23, 95% CI 1.07–1.42, p = 0.003) and LVMI (HR 1.04, 95% CI 1.00–1.08, p = 0.021) were associated with the secondary endpoint. α-Klotho levels had the highest area under the curve (AUC) by ROC analysis, that is, 0.766 (95% CI 0.70–0.82) for the primary endpoint and 0.842 (95% CI 0.79–0.90) for the secondary endpoint with cut-off values of 412 pg/ml (HR 3.06, 95% CI 1.36–6.89, p = 0.007) and 368 pg/ml (HR 4.84, 95% CI 1.59–14.73, p = 0.005), respectively. Conclusion In pre-dialysis CKD patients, α-Klotho levels are associated with all-cause and cardiovascular mortality and may be considered an early prognostic marker. Graphical abstract
- 2 September 2024
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (1) , 171-179
α-Klotho is associated with cardiovascular and all-cause mortality in patients with stage 3b and 4 chronic kidney disease (CKD): a long-term prospective cohort study
Background α-Klotho deficiency may increase cardiovascular risks and worsen survival. We evaluated the association of α-Klotho with cardiovascular and all-cause mortality in pre-dialysis chronic kidney disease (CKD) patients. Methods In this prospective study, 75 non-diabetic CKD stage 3b–4 patients were followed-up for a median of 8 years. Primary and secondary outcomes were all-cause and cardiovascular mortality, respectively. Human soluble α-Klotho ELISA Assay (IBL-Takara 27,998-96Well), Human Fibroblast Growth Factor-23 ELISA Assay (intact FGF23, Merck Millipore MILLENZ FGF23-32 K), and Human Sclerostin ELISA kits (Biomedica, Vienna, BI-20492) were used to measure serum α-Klotho, FGF23 and sclerostin levels in the certified laboratory at the Sechenov University according to the manufacturers’ protocols. All patients underwent echocardiography to evaluate left ventricular mass index (LVMI), left ventricular ejection fraction by Simpson method, and cardiac (valve) calcification score by a semi-quantitative point scale. Lateral abdominal radiography by Kauppila method was used to estimate calcification of the abdominal aorta. Cox multivariate regression and receiver-operating characteristic curve (ROC)-analysis were used to evaluate risk factors for death and their cut-off values. Results Primary and secondary endpoints were reached in 15 (20%) and 9 (12%) patients, respectively. Median α-Klotho levels in deceased and surviving patients were 344 and 484 pg/ml, respectively (p = 0.002). In a multivariate Cox regression model, baseline α-Klotho levels (HR 0.99, 95% CI 0.98–1.00, p = 0.023), aortic calcification (HR 1.18, 95% CI 1.02–1.36, p = 0.029) and left ventricular mass index (LVMI) (HR 1.04, 95% CI 1.00–1.08, p = 0.033) were associated with the primary endpoint, whereas α-Klotho (HR 0.99, 95% CI 0.98–1.00, p = 0.029), aortic calcification (HR 1.23, 95% CI 1.07–1.42, p = 0.003) and LVMI (HR 1.04, 95% CI 1.00–1.08, p = 0.021) were associated with the secondary endpoint. α-Klotho levels had the highest area under the curve (AUC) by ROC analysis, that is, 0.766 (95% CI 0.70–0.82) for the primary endpoint and 0.842 (95% CI 0.79–0.90) for the secondary endpoint with cut-off values of 412 pg/ml (HR 3.06, 95% CI 1.36–6.89, p = 0.007) and 368 pg/ml (HR 4.84, 95% CI 1.59–14.73, p = 0.005), respectively. Conclusion In pre-dialysis CKD patients, α-Klotho levels are associated with all-cause and cardiovascular mortality and may be considered an early prognostic marker. Graphical abstract
- Open Access
- 7 July 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (6) , 606-613
Anemia of chronic diseases in the early stages of chronic kidney disease as a risk factor for cardiovascular complications in patients with glomerulonephritis
Aim. To determine biomarkers of anemia of chronic disease (ACD) in patients with glomerulonephritis (GN) in the early stages of CKD, to assess their role as risk factors for cardiovascular complications (CVС). Materials and methods. Seventy nine patients with GN were studied, among them: 40 with primary сhronic GN (CGN), 39 with secondary forms:19 – GN with ANCA-associated systemic vasculitis, 20 – GN with systemic lupus erythematosus (SLE) at early (all I–II) CKD stages. In all patients, the level of serum C-reactive protein (CRP), hepcidin, interferon γ, and the circulating form of protein Klotho (s-Klotho) were determined. When a relative iron deficiency was detected [transferrin iron saturation coefficient (TSAT) 20%], patients were administered parenterally iron [III] sucrose hydroxide complex (Venofer). Results. The frequency of anemia among patients with systemic diseases is 3.2 times higher than among patients with primary CGN. Patients with anemia (group I; n=43) had higher rates of daily proteinuria (p0.001), systolic blood pressure (p0.05), serum levels of interferon γ (p0.001) and hepcidin (p0.001) and lower values of eGFR (p0.05) than patients without anemia (group II; n=36). A strong inverse correlation was noted between the level of hepcidin and the content of iron in serum (r=-0.856; p0.001), between the level of hemoglobin and the level of interferon γ (r=-0.447; p0.05), hepcidin (r=-0.459; p0.05) and CRP (r=-0.453; p0.05). A significant inverse correlation was found between the level of hemoglobin and CVC risk factors – the value of systolic blood pressure (r=-0.512; p0.05) and the mass index of the left ventricular myocardium (r=-0.619; p0.01). At the same time, the contribution of 2 from 6 analyzed factors, hepcidin and eGFR, to the development of ACD was 92.5%, of which 86.6% accounted for hepcidin. A strong direct correlation was also found between a decrease in hemoglobin level and a decrease in the level of s-Klotho protein (r=0.645; p0.001), a decrease in the level of s-Klotho and an increase in the level of serum hepcidin (r=-0.541; p0.05). The leading value of anemia (beta -0,29; p=0,04) and depression of the s-Klotho level (beta -0,44; p=0,02) as independent cardiovascular risk factors in this group of patients was confirmed by multivariate analysis. In patients with identified deficiency of iron (n=40), after 3–4 weeks of intravenous administration of venofer, the target level of hemoglobin (Нb120 g/l) and transferrin saturation with iron (TSAT20%) were achieved. Conclusion. Among the biomarkers of ACD in patients with immunoinflammatory diseases of the kidneys (primary and secondary СGN), the increase in the serum level of hepcidin is greatest importance. The concomitant to anemia decrease in s-Klotho is a leading risk factor for CVС in CKD. Early correction of ACD with iron supplements makes it possible to achieve target levels of Hb and TSAT and have subsequently a positive effect on the production of s-Klotho and the severity of left ventricular hypertrophia.
- 7 July 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (6) , 606-613
Open AccessAnemia of chronic diseases in the early stages of chronic kidney disease as a risk factor for cardiovascular complications in patients with glomerulonephritis
Aim. To determine biomarkers of anemia of chronic disease (ACD) in patients with glomerulonephritis (GN) in the early stages of CKD, to assess their role as risk factors for cardiovascular complications (CVС). Materials and methods. Seventy nine patients with GN were studied, among them: 40 with primary сhronic GN (CGN), 39 with secondary forms:19 – GN with ANCA-associated systemic vasculitis, 20 – GN with systemic lupus erythematosus (SLE) at early (all I–II) CKD stages. In all patients, the level of serum C-reactive protein (CRP), hepcidin, interferon γ, and the circulating form of protein Klotho (s-Klotho) were determined. When a relative iron deficiency was detected [transferrin iron saturation coefficient (TSAT) 20%], patients were administered parenterally iron [III] sucrose hydroxide complex (Venofer). Results. The frequency of anemia among patients with systemic diseases is 3.2 times higher than among patients with primary CGN. Patients with anemia (group I; n=43) had higher rates of daily proteinuria (p0.001), systolic blood pressure (p0.05), serum levels of interferon γ (p0.001) and hepcidin (p0.001) and lower values of eGFR (p0.05) than patients without anemia (group II; n=36). A strong inverse correlation was noted between the level of hepcidin and the content of iron in serum (r=-0.856; p0.001), between the level of hemoglobin and the level of interferon γ (r=-0.447; p0.05), hepcidin (r=-0.459; p0.05) and CRP (r=-0.453; p0.05). A significant inverse correlation was found between the level of hemoglobin and CVC risk factors – the value of systolic blood pressure (r=-0.512; p0.05) and the mass index of the left ventricular myocardium (r=-0.619; p0.01). At the same time, the contribution of 2 from 6 analyzed factors, hepcidin and eGFR, to the development of ACD was 92.5%, of which 86.6% accounted for hepcidin. A strong direct correlation was also found between a decrease in hemoglobin level and a decrease in the level of s-Klotho protein (r=0.645; p0.001), a decrease in the level of s-Klotho and an increase in the level of serum hepcidin (r=-0.541; p0.05). The leading value of anemia (beta -0,29; p=0,04) and depression of the s-Klotho level (beta -0,44; p=0,02) as independent cardiovascular risk factors in this group of patients was confirmed by multivariate analysis. In patients with identified deficiency of iron (n=40), after 3–4 weeks of intravenous administration of venofer, the target level of hemoglobin (Нb120 g/l) and transferrin saturation with iron (TSAT20%) were achieved. Conclusion. Among the biomarkers of ACD in patients with immunoinflammatory diseases of the kidneys (primary and secondary СGN), the increase in the serum level of hepcidin is greatest importance. The concomitant to anemia decrease in s-Klotho is a leading risk factor for CVС in CKD. Early correction of ACD with iron supplements makes it possible to achieve target levels of Hb and TSAT and have subsequently a positive effect on the production of s-Klotho and the severity of left ventricular hypertrophia.
- Open Access
- 22 August 2023
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 33 (3) , 66-75
A 19-year-old Patient with Recurrent Pruritus and Jaundice
Аim: to highlight the importance of broad differential diagnosis and possibility of conversion of benign recurrent intrahepatic cholestasis type 2 into more aggressive clinical phenotype.Key points. A 19-year-old female patient was admitted to the Clinic with skin pruritus, jaundice, dark urine, clay-colored stool, and general fatigue. Past medical history was significant for recurrent aforementioned symptoms since 3 years old, that relapsed every 1–2 years and were usually ameliorated with conservative therapy. During recent years, frequency of relapses and recovery period increased, at the same time effectiveness of medical therapy decreased. Blood chemistry results revealed an elevation of total bilirubin (up to 634 μmol/L), direct bilirubin (up to 354 μmol/L), bile acids (up to 510 μmol/L) and normal gamma glutamyl transferase level. Workup was negative for viral hepatitis, autoimmune liver diseases, obstructive choledochal lesions, storage diseases, although mutation in gene ABCB11 was found. Benign recurrent intrahepatic cholestasis type 2 was diagnosed. Following conservative therapy and plasmapheresis, jaundice and skin pruritus significantly diminished, levels of bilirubin and bile acids normalized. Regular follow up, liver biopsy and measures for relapse prevention given clinical features of aggressive phenotype were recommended.Conclusion. Identification of etiology of cholestatic liver diseases requires broad differential diagnosis. Clinical course of patients with benign recurrent intrahepatic cholestasis may transform into aggressive phenotype, reminiscent of progressive familial intrahepatic cholestasis.
- 22 August 2023
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 33 (3) , 66-75
Open AccessA 19-year-old Patient with Recurrent Pruritus and Jaundice
Аim: to highlight the importance of broad differential diagnosis and possibility of conversion of benign recurrent intrahepatic cholestasis type 2 into more aggressive clinical phenotype.Key points. A 19-year-old female patient was admitted to the Clinic with skin pruritus, jaundice, dark urine, clay-colored stool, and general fatigue. Past medical history was significant for recurrent aforementioned symptoms since 3 years old, that relapsed every 1–2 years and were usually ameliorated with conservative therapy. During recent years, frequency of relapses and recovery period increased, at the same time effectiveness of medical therapy decreased. Blood chemistry results revealed an elevation of total bilirubin (up to 634 μmol/L), direct bilirubin (up to 354 μmol/L), bile acids (up to 510 μmol/L) and normal gamma glutamyl transferase level. Workup was negative for viral hepatitis, autoimmune liver diseases, obstructive choledochal lesions, storage diseases, although mutation in gene ABCB11 was found. Benign recurrent intrahepatic cholestasis type 2 was diagnosed. Following conservative therapy and plasmapheresis, jaundice and skin pruritus significantly diminished, levels of bilirubin and bile acids normalized. Regular follow up, liver biopsy and measures for relapse prevention given clinical features of aggressive phenotype were recommended.Conclusion. Identification of etiology of cholestatic liver diseases requires broad differential diagnosis. Clinical course of patients with benign recurrent intrahepatic cholestasis may transform into aggressive phenotype, reminiscent of progressive familial intrahepatic cholestasis.
- Open Access
- 17 August 2023
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 95 (6) , 521-525
Cardiorenal syndromes: historical aspects and current challenges
The article describes major milestones in acknowledgment of pathophysiological relationship between heart and kidneys since Ancient Egypt till our time and history of term cardiorenal syndrome (CRS). First references about kidney and heart functions could be dated to 13 BC when Hippocrates mentioned them. In the XIV century Gentile da Foligno proposed a hypothesis about functional interconnection between heart and kidneys. In the XVIII century Richard Bright described the link between myocardial hypertrophy and kidneys diseases. Frederic Justin Collet was the first one who used the term cardiorenal in his article in 1903. In Russia, I.I. Stolnikov conducted his experiments about myocardial hypertrophy and kidneys ischemia in 1880. Famous Russian internist, E.M. Tareev, devoted several paragraphs to cardiorenal interactions in his fundamental manuals Anemia in Brights disease (1929) and Hypertension (1948). The research on this topic was continued by Tareevs followers: N.A. Mukhin, V.S. Moiseev, more recent successors Zh.D. Kobalava, S.V. Moiseev, V.V. Fomin, S.V. Villevalde and others. Their contribution resulted in development of first Russian clinical guidelines on cardio and nephroprotection in CRS in 2014. In 2008 consensus of Acute Disease Quality Initiative summarized current experience on CRS. Today, research on controversial classification questions, biomarkers and other aspects of CRS continues.
- 17 August 2023
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 95 (6) , 521-525
Open AccessCardiorenal syndromes: historical aspects and current challenges
The article describes major milestones in acknowledgment of pathophysiological relationship between heart and kidneys since Ancient Egypt till our time and history of term cardiorenal syndrome (CRS). First references about kidney and heart functions could be dated to 13 BC when Hippocrates mentioned them. In the XIV century Gentile da Foligno proposed a hypothesis about functional interconnection between heart and kidneys. In the XVIII century Richard Bright described the link between myocardial hypertrophy and kidneys diseases. Frederic Justin Collet was the first one who used the term cardiorenal in his article in 1903. In Russia, I.I. Stolnikov conducted his experiments about myocardial hypertrophy and kidneys ischemia in 1880. Famous Russian internist, E.M. Tareev, devoted several paragraphs to cardiorenal interactions in his fundamental manuals Anemia in Brights disease (1929) and Hypertension (1948). The research on this topic was continued by Tareevs followers: N.A. Mukhin, V.S. Moiseev, more recent successors Zh.D. Kobalava, S.V. Moiseev, V.V. Fomin, S.V. Villevalde and others. Their contribution resulted in development of first Russian clinical guidelines on cardio and nephroprotection in CRS in 2014. In 2008 consensus of Acute Disease Quality Initiative summarized current experience on CRS. Today, research on controversial classification questions, biomarkers and other aspects of CRS continues.
- 13 November 2022
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 33 (3) , 435-442
Soy Protein as a Part of a Low-protein Diet is a New Direction in Cardio- and Nephroprotection in Patients With 3b-4 Stages of Chronic kidney Disease
- 13 November 2022
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 33 (3) , 435-442
Soy Protein as a Part of a Low-protein Diet is a New Direction in Cardio- and Nephroprotection in Patients With 3b-4 Stages of Chronic kidney Disease